Non-alcoholic fatty liver (NAFLD) refers to a wide spectrum of liver disorders ranging from hepatic steatosis to nonalcoholic steatohepatitis, fibrosis and cirrhosis. NAFLD is often associated with obesity, insulin resistance, type 2 diabetes and dyslipidemia. Farnesoid X receptor (FXR) is a nuclear hormone receptor and plays an important role in maintaining bile acid, lipid and glucose homeostasis. Our long-term goal is to identify novel genes/pathways that regulate lipid and carbohydrate metabolism and to elucidate the underlying mechanism(s). Activation of FXR has been shown to lower both hepatic and plasma triglyceride levels. While the mechanism by which FXR regulates plasma triglyceride levels is well understood, the mechanism whereby activation of FXR lowers hepatic triglyceride levels remains to be elucidated. Recent data have suggested that FXR is a therapeutic target for treatment of NAFLD. Thus, elucidation of the mechanism by which activation of FXR lowers hepatic triglyceride levels is both important and necessary. Carboxylesterase 1 (CES1) is highly and principally expressed in the liver. Our preliminary data have shown that i) high blood glucose levels induce hepatic CES1 expression, ii) over-expression of hepatic CES1 markedly reduces hepatic triglyceride levels, lowers plasma glucose levels, and improves glucose tolerance, iii) loss of hepatic CES1 significantly increases hepatic triglyceride levels, and iv) activation of FXR highly induces hepatic CES1 expression. These preliminary data are quite exciting, as they provide the first in vivo evidence that hepatic CES1 may play an important role in regulating hepatic triglyceride and glucose homeostasis. In this proposal, we will further determine the role of hepatic CES1 in controlling glucose and hepatic triglyceride homeostasis and in FXR signaling. We will utilize genetically modified mice, in combination with biochemical, molecular and cellular, and pharmacological approaches to finish the proposed studies. Accomplishing the specific aims in this proposal will provide important insights into the mechanism by which FXR regulates hepatic triglyceride levels, and may identify a novel CES1-glucose-Ces1 pathway that regulates plasma glucose levels. Finally, completion of the proposed studies may lead to identification of hepatic CES1 as a therapeutic target for treatment of NAFLD.

Public Health Relevance

Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases in humans. Completion of the proposed studies will help determine how FXR regulates hepatic triglyceride metabolism and whether hepatic carboxylesterase 1 is a potential target for treatment of NAFLD. Thus, the studies proposed in this application are highly relevant to fatty liver disease and human health.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project (R01)
Project #
Application #
Study Section
Hepatobiliary Pathophysiology Study Section (HBPP)
Program Officer
Laughlin, Maren R
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Northeast Ohio Medical University
Other Basic Sciences
Schools of Medicine
United States
Zip Code
You, Min; Jogasuria, Alvin; Lee, Kwangwon et al. (2017) Signal Transduction Mechanisms of Alcoholic Fatty Liver Disease: Emer ging Role of Lipin-1. Curr Mol Pharmacol 10:226-236
Zhang, Guoning; Liu, Shuainan; Tan, Wenjuan et al. (2017) Synthesis and biological evaluations of chalcones, flavones and chromenes as farnesoid x receptor (FXR) antagonists. Eur J Med Chem 129:303-309
Xu, Jiesi; Xu, Yang; Xu, Yanyong et al. (2017) Global inactivation of carboxylesterase 1 (Ces1/Ces1g) protects against atherosclerosis in Ldlr -/- mice. Sci Rep 7:17845
Xu, Jiesi; Xu, Yang; Li, Yuanyuan et al. (2016) Carboxylesterase 1 Is Regulated by Hepatocyte Nuclear Factor 4? and Protects Against Alcohol- and MCD diet-induced Liver Injury. Sci Rep 6:24277
Li, Yuanyuan; Zalzala, Munaf; Jadhav, Kavita et al. (2016) Carboxylesterase 2 prevents liver steatosis by modulating lipolysis, endoplasmic reticulum stress, and lipogenesis and is regulated by hepatocyte nuclear factor 4 alpha in mice. Hepatology 63:1860-74
Xu, Yang; Li, Fei; Zalzala, Munaf et al. (2016) Farnesoid X receptor activation increases reverse cholesterol transport by modulating bile acid composition and cholesterol absorption in mice. Hepatology 64:1072-85
Guarini, Giacinta; Kiyooka, Takahiko; Ohanyan, Vahagn et al. (2016) Impaired coronary metabolic dilation in the metabolic syndrome is linked to mitochondrial dysfunction and mitochondrial DNA damage. Basic Res Cardiol 111:29
Xu, Yang; Zalzala, Munaf; Xu, Jiesi et al. (2015) A metabolic stress-inducible miR-34a-HNF4? pathway regulates lipid and lipoprotein metabolism. Nat Commun 6:7466
Xu, Jiesi; Li, Yuanyuan; Chen, Wei-Dong et al. (2014) Hepatic carboxylesterase 1 is essential for both normal and farnesoid X receptor-controlled lipid homeostasis. Hepatology 59:1761-1771
Xu, Jiesi; Yin, Liya; Xu, Yang et al. (2014) Hepatic carboxylesterase 1 is induced by glucose and regulates postprandial glucose levels. PLoS One 9:e109663

Showing the most recent 10 out of 11 publications